A randomized, controlled, double-blind study of Fuzheng Jiedu granules in combination with icotinib in the first-line treatment of EGFR-sensitive mutated advanced lung adenocarcinoma

Category Primary study
Registry of TrialsInternational Traditional Medicine Clinical Trial Registry
Year 2020
This article has no abstract
Epistemonikos ID: 3bc90339fb9b51c659806c8a8fdfe29ed2461bb2
First added on: Apr 11, 2025